
Sign up to save your podcasts
Or


Send us a text
This conversation begins with a broader look at the strategies behind developing combination agents and the role these combination therapies will play in what Mazen Noureddin describes as the coming “combo-combo” world.
The group agrees that 2 or 3 agents are the most they can see in a combination therapy at this time. They all agree that some patients will require combination therapies while others will succeed with monotherapies. This will be linked with disease severity. Naim Alkhouri shares another long term study he is working on.
By SurfingNASH.com3.9
2424 ratings
Send us a text
This conversation begins with a broader look at the strategies behind developing combination agents and the role these combination therapies will play in what Mazen Noureddin describes as the coming “combo-combo” world.
The group agrees that 2 or 3 agents are the most they can see in a combination therapy at this time. They all agree that some patients will require combination therapies while others will succeed with monotherapies. This will be linked with disease severity. Naim Alkhouri shares another long term study he is working on.

32,291 Listeners

30,851 Listeners

9,747 Listeners

105 Listeners

21,261 Listeners

3,378 Listeners

113,258 Listeners

57,057 Listeners

9,583 Listeners

8,724 Listeners

10,273 Listeners

6,470 Listeners

0 Listeners

419 Listeners

678 Listeners